Ketamine Therapy While Taking Ozempic, Wegovy, or Mounjaro: What to Know

A version of this question has come up in almost every evaluation I've done in the past six months: "I'm on Ozempic — can I still do ketamine?" The short answer is yes, in nearly every case. GLP-1 receptor agonists — Ozempic and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide), Saxenda and Victoza (liraglutide), and a handful of others — don't share a receptor system with ketamine. There's no direct pharmacological conflict, no dose adjustment required on either side, and no particular reason to pause either medication just because you're starting the other.

That's the direct answer. The longer answer is worth having because these two medication classes do overlap in one specific area that matters on session day, and a patient who doesn't know about the overlap can have a much rougher first session than they needed to.

Why there's no direct interaction

GLP-1 drugs work on glucagon-like peptide-1 receptors, which are involved in glucose regulation, gastric emptying, and appetite. They slow how quickly food leaves your stomach, they increase insulin release in response to meals, and they produce satiety signals in the brain's hypothalamus and brainstem. That's the pharmacology that makes them effective for type 2 diabetes and, at higher doses, for weight management.

Ketamine works on NMDA glutamate receptors in the cortex. It blocks those receptors non-competitively, triggers a downstream cascade of AMPA activation and BDNF release, and produces the neuroplastic window that makes it effective for treatment-resistant depression, anxiety, and PTSD. The mechanism is entirely separate from the GLP-1 pathway — different receptors, different neurotransmitters, different brain regions doing most of the work.

Pharmacologically, these drugs coexist the same way blood pressure medication coexists with an antibiotic. They're operating in different systems.

The real overlap: nausea and gastric emptying

Here's the thing the direct-interaction answer misses. Both medications, independently, can produce nausea — and the mechanisms overlap in ways that matter for session design.

GLP-1 drugs cause nausea by slowing gastric emptying. Food sits in the stomach longer than it normally would. For most patients on stable doses, this is subclinical — you feel fuller longer, you eat less, and that's the point. But for patients who are titrating up, who missed the prior dose and restarted, or who ate something rich shortly before the session, the stomach can still be holding food hours after you'd expect it to be empty.

Ketamine, particularly sublingual ketamine at antidepressant doses, can produce nausea independently. The mechanism is different — it's primarily a central effect mediated by the chemoreceptor trigger zone — but the subjective experience is the same: queasy, unsettled, occasionally vomiting.

Add those two together during a session and you have a patient who is more likely to experience nausea, and whose nausea may be harder to resolve quickly because the stomach is genuinely fuller than it would otherwise be.

What I actually ask patients to do

The practical guidance I give patients on GLP-1 medications looks like this:

Continue the GLP-1 as prescribed. Don't stop it for the ketamine session. There's no clinical reason to, and interrupting a GLP-1 course unnecessarily disrupts the metabolic work it's doing.

Extend the pre-session fasting window. Standard guidance for a ketamine session is a light meal 2–3 hours beforehand and nothing heavy for about 90 minutes before dosing. For patients on GLP-1 medications, I extend that — no solid food for 4–6 hours before the session, and nothing greasy or protein-heavy on the day of. Clear fluids up to about 2 hours before are fine. The goal is a stomach that's genuinely empty by the time the ketamine kicks in.

Pre-medicate with an antiemetic if you've had nausea on GLP-1 in the past. Ondansetron 4 mg (Zofran) taken 30–60 minutes before the session substantially reduces the probability of intra-session nausea. I prescribe this routinely for patients whose GLP-1 history includes nausea, and opportunistically for other patients who want the prophylaxis. It has essentially no downside at a single 4 mg dose.

Keep the injection day separate from the ketamine session day, when you can. If you take Ozempic on Sunday mornings, schedule your ketamine sessions for Tuesdays, Wednesdays, or Thursdays rather than the 24 hours after your weekly injection. The nausea peak for GLP-1 drugs is typically in the day or two after the injection; avoiding that window reduces the overlap.

Hydrate aggressively the day before. GLP-1 drugs reduce thirst signaling for a lot of patients, and dehydration makes nausea worse. A large glass of water the night before and another an hour before the session helps.

When a pause might be reasonable

There are a small number of scenarios where I might suggest holding a GLP-1 dose around a session. The most common is a patient who has had significant nausea on their most recent dose increase and is clearly still titrating. In that specific case, pushing through a ketamine session with unresolved GLP-1 nausea is counterproductive — the session is miserable, the patient may not want to do another, and the antidepressant effect is probably dulled by the body being preoccupied with feeling sick.

In those cases, I coordinate with the patient's prescribing physician for the GLP-1 to either time the session away from the most recent dose or temporarily hold the next dose until after the first ketamine session. This is a conversation, not a unilateral recommendation — the GLP-1 is doing real work, and you don't want to disrupt that trajectory unless there's a clear reason.

What GLP-1 drugs don't change

It's worth being explicit about what the GLP-1 does not affect, because patients sometimes assume it complicates the ketamine process more than it does.

Your dissociative experience. Ketamine's subjective effects during the session — the floating quality, the altered perception of time, the emotional openness — are not affected by whether you're on a GLP-1. Same session, same experience.

Your antidepressant response. There's no evidence that GLP-1 medications blunt or enhance ketamine's antidepressant effect. The neuroplastic cascade that produces the therapeutic response runs through entirely separate machinery.

Your cardiovascular monitoring requirements. The blood pressure and heart rate monitoring during a ketamine session is the same regardless. GLP-1 medications don't add any cardiovascular concern to the ketamine session itself.

Your long-term treatment plan. Once you've worked through the initial session logistics, ongoing ketamine therapy and ongoing GLP-1 therapy coexist routinely. Most of my patients on GLP-1 medications are stable on them throughout their ketamine course, and we don't think about it again after we've set up the session-day plan.

An honest note about the overlap between these patient populations

Clinically, it's worth saying out loud that there's meaningful overlap between the patients who benefit from ketamine and the patients who benefit from GLP-1 medications. Treatment-resistant depression and metabolic dysfunction travel together more often than chance would predict — both share inflammatory pathways, both correlate with adverse childhood experiences, both are undertreated in primary care. Some of my patients arrive already on a GLP-1 and get started on ketamine; some arrive on ketamine and start a GLP-1 later. The combination is often more than the sum of its parts — mood improves, energy improves, weight comes down, self-perception improves, and those effects compound.

This isn't a reason to combine the medications if only one is clinically indicated. But it is a reason not to see them as fundamentally in tension. They're addressing different aspects of the same underlying biology in many patients, and a thoughtful coordinated plan tends to produce better results than either medication alone.

If you're considering ketamine and you're on a GLP-1

The conversation is straightforward. The GLP-1 continues. Session-day logistics get a little more attention than they otherwise would. We plan around the injection schedule when it's easy to do so. You get the clinical benefit of both treatments without either one undercutting the other.

If you're ready to find out whether ketamine is a fit for your situation, our eligibility check is the entry point. The screening asks about current medications, including GLP-1 agents, and the result is honest — if ketamine isn't the right tool for you, I'll tell you why.

— Dr. Ben Soffer

Related reading: ketamine and SSRIs like Lexapro, ketamine with benzodiazepines, what to eat before and after a session, safety and side effects, what a session actually feels like.